KRKG Stock Overview
A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €168.50 |
| 52 Week High | €174.00 |
| 52 Week Low | €122.00 |
| Beta | 0.50 |
| 1 Month Change | 0.30% |
| 3 Month Change | 18.66% |
| 1 Year Change | 36.44% |
| 3 Year Change | 89.33% |
| 5 Year Change | 127.09% |
| Change since IPO | 2,024.45% |
Recent News & Updates
Recent updates
Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?
Apr 01
Is Krka, d. d. (LJSE:KRKG) Trading At A 32% Discount?
Jan 14Krka, d. d.'s (LJSE:KRKG) Share Price Could Signal Some Risk
Dec 13Krka, d. d.'s (LJSE:KRKG) Shareholders Might Be Looking For Exit
Aug 27Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?
Aug 09Krka d. d (LJSE:KRKG) Is Paying Out A Larger Dividend Than Last Year
Jul 22Krka d. d (LJSE:KRKG) Will Pay A Larger Dividend Than Last Year At €7.50
Jun 11Shareholder Returns
| KRKG | SI Pharmaceuticals | SI Market | |
|---|---|---|---|
| 7D | 6.6% | -1.4% | 1.8% |
| 1Y | 36.4% | -19.7% | 31.7% |
Return vs Industry: KRKG exceeded the SI Pharmaceuticals industry which returned -19.7% over the past year.
Return vs Market: KRKG exceeded the SI Market which returned 31.7% over the past year.
Price Volatility
| KRKG volatility | |
|---|---|
| KRKG Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in SI Market | 6.1% |
| 10% least volatile stocks in SI Market | 3.7% |
Stable Share Price: KRKG has not had significant price volatility in the past 3 months compared to the SI market.
Volatility Over Time: KRKG's weekly volatility (4%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 11,308 | Jože Colaric | www.krka.biz |
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, infections, oncology, and other diseases. It provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.
Krka, d. d. Fundamentals Summary
| KRKG fundamental statistics | |
|---|---|
| Market cap | €5.16b |
| Earnings (TTM) | €356.99m |
| Revenue (TTM) | €1.91b |
14.4x
P/E Ratio2.7x
P/S RatioIs KRKG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRKG income statement (TTM) | |
|---|---|
| Revenue | €1.91b |
| Cost of Revenue | €815.66m |
| Gross Profit | €1.09b |
| Other Expenses | €736.90m |
| Earnings | €356.99m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 15, 2025
| Earnings per share (EPS) | 11.67 |
| Gross Margin | 57.29% |
| Net Profit Margin | 18.69% |
| Debt/Equity Ratio | 0% |
How did KRKG perform over the long term?
See historical performance and comparisonDividends
4.5%
Current Dividend Yield64%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 08:47 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krka, d. d. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saso Stanovnik | Alta Invest |
| Simon Mather | Barclays |
| Stephane Sumar | BNP Paribas Exane |